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Inflammation is a critical mechanism of atherosclerosis [1] . As the inflammatory feature of atherosclerosis was proposed decades ago [2] , there have been continuous efforts to defining the underlying molecular mechanisms. Recent interest has been focusing on inflammasomes, a component of the Cholesterol crystal accumulation in macrophages is a common feature of atherosclerosis. Duewell et al. [5] discovered that cholesterol crystals in macrophages activated nucleotide-binding oligomerization domain receptors (NLRP)3 inflammasomes. Deficiency of inflammasome components such as NLRP3 or apoptosis-associated speck-like protein (ASC) containing a caspase activation and recruitment domain (CARD) in bone marrow-derived cells profoundly reduced hypercholesterolemia-induced atherosclerosis in mice [5] . On the basis of this premise, Sheedy et al. [3 && ] performed a series of experiments to define potential mechanisms by which NLRP3 inflammasomes are activated by oxidized LDL. Using cultured macrophages, the authors demonstrated CD36-mediated oxidized LDL uptake and subsequent generation of intracellular cholesterol crystals. CD36 was crucial in both the priming and activation of NLRP3 inflammasomes, which led to release of interleukin-1b. These in vitro data were congruent with in vivo findings that deficiency or inhibition of CD36 diminished NLRP3 inflammasome activation in apolipoprotein (apo)E À/À mice fed a saturated fat enriched diet. Deficiency of CD36 not only reduced plasma interleukin-1b concentrations and atherosclerotic lesion areas, but also diminished cholesterol crystal accumulation in atherosclerotic lesions of apoE À/À mice fed the saturated fat-enriched diet. Together, these data implicate a novel mechanism that CD36mediated inflammasome activation promotes atherosclerosis.
Although the findings by Sheedy et al. [3 && ] provide evidence that cholesterol crystal-induced NLRP3 inflammasome activation exerts a critical role in promoting atherosclerosis, there is also evidence that inflammasome-independent mechanisms are important for atherosclerotic development [6] . In contrast to studies reported by Duewell et al. [5] that NLRP3 inflammasome component deficiency in bone marrow-derived cells reduced atherosclerosis in LDL receptor À/À chimeric mice, Menu et al. [6] demonstrated that whole body deficiency of NLRP3 inflammasome components (NLRP-3, ASC or caspase-1) had no effects on atherosclerosis in apoE À/À mice. NLRP3 inflammasome activation induced secretion of both interleukin-1a and interleukin-1b [3 && ,7]. Interestingly, although whole body deficiency of either interleukin-1 subtypes led to equivalent reductions of atherosclerosis in apoE À/À mice [8] , deficiency of interleukin-1a, but not interleukin-1b, in bone marrow-derived cells reduced atherosclerosis in apoE À/À or C57BL/6 mice [8, 9] . In agreement with these studies [8, 9] , Freigang et al. [4 && ] found that interleukin-1a deficiency, but not interleukin-1b deficiency, in bone marrow-derived cells reduced atherosclerosis in LDL receptor À/À chimeric mice fed a cholesterol-enriched diet. The authors found that fatty acids, especially oleic acid, were abundant in atherosclerotic lesions and their abundance in lesions was increased progressively during protract feeding of the cholesterol-enriched diet. Oleic acid induced secretion of interleukin-1a, but not intreleukin-1b, which was independent of NLRP3 inflammasome activation because deficiency of NLRP3 or caspase-1 did not affect oleic acid-induced interleukin-1a secretion. Subsequent experiments demonstrated that a diet containing high oleic acid did not increase plasma cholesterol concentrations in apoE À/À mice, but induced foam cell formation and augmented atherosclerotic lesions compared with apoE À/À mice fed a normal laboratory diet. The authors also provided compelling evidence that oleic acid-induced interleukin-1a secretion was mediated by mitochondrial uncoupling.
The findings by Sheedy et al. [3 && ] and Freigang et al. [4 && ] implicate that these two interleukin-1 subtypes contribute to atherosclerosis through different mechanisms. Therefore, inhibition of both interleukin-1 subtypes may provide more profound beneficial effects on atherosclerosis [5] . A clinical trial (CANTOS; NCT01327846) to assess effects of interleukin-1b inhibition on coronary artery disease is currently ongoing [10] . Completion of this clinical trial will provide insights into recognizing whether inhibition of interleukin-1b alone provides beneficial effects on atherosclerosis, or inhibition of both interleukin-1 subtypes should be considered.
